NVONYSE

Novo Nordisk A/S Sponsored ADR

Yahoo Finance

Loading price data…

Recent & upcoming events

The next earnings date isn't available yet.

Company news

Mar 19, 2026 FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

Is this information incorrect?

Data provided by Twelve Data

Save to calendar

Company info

Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.

Ticker NVO

Industry Drug Manufacturers - General

Sector Health Care

Privacy Policy Terms of Service Commercial Transactions Disclosure Billing & Cancellation Advertising Policy Licenses Status 日本語

Novo Nordisk A/S Sponsored ADR

Share screenshot

Recent & upcoming events

Company news